Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.

Zhao, Qiuling; Xie, Ruixiang; Zhong, Wanfu; Liu, Wenbin; Chen, Ting; Qiu, Xiuliang; Yang, Lin

Zhao, Qiuling; Xie, Ruixiang; Zhong, Wanfu; Liu, Wenbin; Chen, Ting; Qiu, Xiuliang; Yang, Lin.

Afiliación

Zhao Q; Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Xie R; Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Zhong W; Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Liu W; Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Chen T; Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Qiu X; Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Yang L; Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. apera@163.com.

Cost Eff Resour Alloc ; 21(1): 19, 2023 Mar 01.

Article en En | MEDLINE | ID: mdl-36859267

Palabras clave

Biliary tract cancer; Cost-effectiveness analysis; Durvalumab; First-line treatment; PD-L1

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Cost Eff Resour Alloc Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google